Related references
Note: Only part of the references are listed.Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu et al.
CLINICAL CANCER RESEARCH (2017)
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells
Thomas Schirdewahn et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen
S. Rafiq et al.
LEUKEMIA (2017)
Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments
Timothy J. Egan et al.
MABS (2017)
A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis
Yaron Ilan et al.
IMMUNOBIOLOGY (2017)
Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies
Bryan C. Barnhart et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Megan Lo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Self-assembled protein nanocarrier for intracellular delivery of antibody
Sung In Lim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
The use of immunotherapy in the treatment of melanoma
Tala Achkar et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
An Fc-Silenced IgG1 Format With Extended Half-Life Designed for Improved Stability
M. Jack Borrok et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein
Ruben J. Boado et al.
MOLECULAR PHARMACEUTICS (2017)
Integration of a CD19 CAR into the. TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
Daniel T. MacLeod et al.
MOLECULAR THERAPY (2017)
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Malika Hale et al.
MOLECULAR THERAPY (2017)
CAR T therapies drive into new terrain
Katie Kingwell
NATURE REVIEWS DRUG DISCOVERY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
Yajuan Zhou et al.
ONCOTARGET (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
Shunsuke Chikuma et al.
CANCER SCIENCE (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Carlos Alberto Fajardo et al.
CANCER RESEARCH (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
Michela Silacci et al.
MABS (2016)
Surgical immune interventions for solid malignancies
Masha Zeltsman et al.
AMERICAN JOURNAL OF SURGERY (2016)
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
Silvia Carvalho et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Eugene A. Zhukovsky et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Harnessing Fc receptor biology in the design of therapeutic antibodies
Peter Sondermann et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Immunocytokines for cancer treatment: past, present and future
Dario Neri et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Immunoglobulin isotype knowledge and application to Fc engineering
Randall J. Brerski et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Targeting the EGF/HER Ligand-Receptor System in Cancer
Azucena Esparis-Ogando et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1
Carl I. Webster et al.
FASEB JOURNAL (2016)
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
Tomoyuki Igawa et al.
IMMUNOLOGICAL REVIEWS (2016)
Pan-HERAn antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers
Sofie Ellebaek et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape
Ji-Sun Kim et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
Erika M. Cook et al.
JOURNAL OF IMMUNOLOGY (2016)
Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates
Chad E. Mire et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Aman P. Singh et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
Andrew D. Tustian et al.
MABS (2016)
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Ilkka Liikanen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos et al.
MOLECULAR CANCER THERAPEUTICS (2016)
In vitro and ex vivo strategies for intracellular delivery
Martin P. Stewart et al.
NATURE (2016)
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
Michiel van der Vlist et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
Thomas Luke et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor et al.
SEMINARS IN IMMUNOLOGY (2016)
Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques
Jenny A. Greig et al.
VACCINE (2016)
Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates
Pamela Thompson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
被撤回的出版物: Receptor tyrosine kinases in carcinogenesis (Retracted article. See vol. 20, 2020)
Xiao-Ying Zhang et al.
ONCOLOGY LETTERS (2016)
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
Marco Ruella et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Kum Ja Lee et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
Ji-Hee Ha et al.
FRONTIERS IN IMMUNOLOGY (2016)
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Sebastian Carotta
FRONTIERS IN IMMUNOLOGY (2016)
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter et al.
ONCOIMMUNOLOGY (2016)
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
Sebastian P. Fuchs et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Immuno-oncology combinations: raising the tail of the survival curve
Sarnuel J. Harris et al.
CANCER BIOLOGY & MEDICINE (2016)
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
Sebastian P. Fuchs et al.
PLOS ONE (2016)
Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics
Peter Lonn et al.
SCIENTIFIC REPORTS (2016)
Spontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates
Vanessa Siegmund et al.
SCIENTIFIC REPORTS (2016)
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Adam R. Root et al.
ANTIBODIES (2016)
Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM
Veronika Chromikova et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2015)
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
William R. Strohl
BIODRUGS (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
Alexander V. Yurkovetskiy et al.
CANCER RESEARCH (2015)
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 Don't Eat Me Signals
Melissa N. McCracken et al.
CLINICAL CANCER RESEARCH (2015)
An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety
Penelope M. Drake et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia
Marco Ruella et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy
Jose A. Figueroa et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2015)
Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial
Gadi Lalazar et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2015)
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Yun Shi et al.
JOURNAL OF IMMUNOLOGY (2015)
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
Li Liu et al.
JOURNAL OF VIROLOGY (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Amita Datta-Mannan et al.
MABS (2015)
Boosting antibody developability through rational sequence optimization
Daniel Seeliger et al.
MABS (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
F. Lhospice et al.
MOLECULAR PHARMACEUTICS (2015)
A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis
Kin-Mei Leung et al.
MOLECULAR THERAPY (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology
Maya Suzuki et al.
PEDIATRIC BLOOD & CANCER (2015)
Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
Marion Adelfinger et al.
VIRUSES-BASEL (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Genenames.org: the HGNC resources in 2015
Kristian A. Gray et al.
NUCLEIC ACIDS RESEARCH (2015)
Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle
Hiroaki Matsushita et al.
PLOS ONE (2015)
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency
Roger R. Beerli et al.
PLOS ONE (2015)
Insulin Receptor Antibody-Iduronate 2-Sulfatase Fusion Protein: Pharmacokinetics, Anti-Drug Antibody, and Safety Pharmacology in Rhesus Monkeys
Ruben J. Boado et al.
BIOTECHNOLOGY AND BIOENGINEERING (2014)
Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers
T. Du et al.
CANCER GENE THERAPY (2014)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
Giovanna Bossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice against Influenza Virus
Virginie S. Adam et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
Probody therapeutics for targeting antibodies to diseased tissue
Krishna R. Polu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
A novel platform for engineering blood-brain barrier-crossing bispecific biologics
Graham K. Farrington et al.
FASEB JOURNAL (2014)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Markus Chmielewski et al.
IMMUNOLOGICAL REVIEWS (2014)
The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer
Teresa Hemmerle et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Simon Brack et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs
Rutilio H. Clark et al.
MABS (2014)
Delivery of antibodies to the cytosol Debunking the myths
Andrea L. J. Marschall et al.
MABS (2014)
Rituximab How approval history is reflected by a corresponding patent filing strategy
Ulrich Storz
MABS (2014)
A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells
Dong-Ki Choi et al.
MABS (2014)
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
Bing Li et al.
MABS (2014)
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
Alejandro B. Balazs et al.
NATURE MEDICINE (2014)
Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
Jens Niewoehner et al.
NEURON (2014)
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
Omid Vafa et al.
METHODS (2014)
Triple Immunoglobulin Gene Knockout Transchromosomic Cattle: Bovine Lambda Cluster Deletion and Its Effect on Fully Human Polyclonal Antibody Production
Hiroaki Matsushita et al.
PLOS ONE (2014)
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Y. Joy Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Passive Immunization against HIV/AIDS by Antibody Gene Transfer
Lili Yang et al.
VIRUSES-BASEL (2014)
Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency
Chris Hughes et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Adeno-associated virus delivery of broadly neutralizing antibodies
Bruce C. Schnepp et al.
CURRENT OPINION IN HIV AND AIDS (2014)
Vector-Mediated In Vivo Antibody Expression
Bruce C. Schnepp et al.
MICROBIOLOGY SPECTRUM (2014)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
Josee Golay et al.
BLOOD (2013)
Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake
Boris Gorovits et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Two-in-One antibodies with dual action Fabs
Charles Eigenbrot et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Potential therapeutic roles for antibody mixtures
T. Shantha Raju et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors
Alessandro Satta et al.
FUTURE ONCOLOGY (2013)
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions
Michelle Kinder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
Siva Charan Devanaboyina et al.
MABS (2013)
Improving biophysical properties of a bispecific antibody scaffold to aid developability Quality by molecular design
Thomas Spreter Von Kreudenstein et al.
MABS (2013)
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Zenjiro Sampei et al.
PLOS ONE (2013)
Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
Tomoyuki Igawa et al.
PLOS ONE (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza
Maria P. Limberis et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells
Gautam K. Sahu et al.
VIROLOGY (2013)
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
Nadine Pasche et al.
CLINICAL CANCER RESEARCH (2012)
Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity
Juergen Hess et al.
FUTURE ONCOLOGY (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Oran Erster et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Pavel Strop et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Thomas C. Nesspor et al.
JOURNAL OF MOLECULAR RECOGNITION (2012)
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Christian Klein et al.
MABS (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin Receptor
Ruben J. Boado et al.
DRUG METABOLISM AND DISPOSITION (2012)
Targeting T Cells with Bispecific Antibodies for Cancer Therapy
Lawrence G. Lum et al.
BIODRUGS (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Highly Efficient Deletion of FUT8 in CHO Cell Lines Using Zinc-Finger Nucleases Yields Cells That Produce Completely Nonfucosylated Antibodies
Laetitia Malphettes et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies
Robert M. Sharkey et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs
Robert M. Anthony et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Internalizing Cancer Antibodies from Phage Libraries Selected on Tumor Cells and Yeast-Displayed Tumor Antigens
Yu Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius et al.
MABS (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Structure and function of the blood-brain barrier
N. Joan Abbott et al.
NEUROBIOLOGY OF DISEASE (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Optimization of Fc-mediated effector functions of monoclonal antibodies
William R. Strohl
CURRENT OPINION IN BIOTECHNOLOGY (2009)
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Michael P. Cancro et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn
Kristi Baker et al.
SEMINARS IN IMMUNOPATHOLOGY (2009)
When binding is enough: nonactivating antibody formats
Aran F. Labrijn et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
BiTE: a new class of antibodies that recruit T-cells
P. A. Baeuerle et al.
DRUGS OF THE FUTURE (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Enzyme replacement therapy for murine hypophosphatasia
Jose Luis Millan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier
Ruben J. Boado et al.
BIOTECHNOLOGY AND BIOENGINEERING (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC
Yutaka Kanda et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II
C Ferrara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells
A Abulrob et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
B Schlereth et al.
CANCER RESEARCH (2005)
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
AC Lazar et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor
JJ Li et al.
CANCER GENE THERAPY (2004)
Establishment of FUT8 knockout Chinese hamster ovary cells:: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
N Yamane-Ohnuki et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand
J Madrenas et al.
JOURNAL OF IMMUNOLOGY (2004)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial
EHS Choy et al.
RHEUMATOLOGY (2002)
Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer
AD Lewis et al.
JOURNAL OF VIROLOGY (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
C Halin et al.
NATURE BIOTECHNOLOGY (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Antibody-cytokine fusion proteins for the therapy of cancer
ML Penichet et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Selection of tumor-specific internalizing human antibodies from phage libraries
MA Poul et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
